One of my most exciting activities during my time at ECVAM was attending ECVAM workshops. Small groups of experts from different backgrounds met together to discuss complex issues, often going through periods of bitter hostility and disagreement, before reaching a set of amicably agreed conclusions.
The workshop on The Use of Transgenic Animals in the European Union, 1 held at Southwell, near Nottingham, on 7-11 April 1997, was no exception to this pattern, especially as the 16 participants ranged from those involved in the production and use of transgenic animals to those tending to be opposed to any such production or use.
One of the 53 conclusions and recommendations was particularly important to me, namely, Conclusion 7: "Certain uses of transgenic animals (for example, the use of higher non-human primates) should be considered, in principle, to be unacceptable".
Given my own commitment to the zero option for the use of non-human primates as laboratory animals, 2 I would have preferred the word higher to have been omitted, but one of the obvious lessons quickly learned when taking part in ECVAM workshops (which would serve human affairs well in many other situations), is that not all the participants can have everything that they want.
The important point was that, even those professionally involved in, and committed to, the production, maintenance and use of transgenic animals, could agree that there were limits which should not be passed.
Sadly, not everybody accepts this.
Earlier this year, I was a speaker in a discussion meeting entitled GM Animals: Pros and Cons, held at the Royal Society on 12 June. One of the three other speakers was Professor Patrick Bateson, Chairman of the Royal Society Working Group, which, in 2001, produced a report, The Use of Genetically Modified Animals. 3 During the 12 June discussion (on which a full report is available on the Internet 4 ), I asked whether Professor Bateson would put any limits on the production of transgenic animals, such as, for example, the production of transgenic non-human primates. I was disappointed, and not a little surprised, when he said that he would not.
I was reminded of this more recently, when I read the evidence given by Professor Alan Goldberg to the House of Lords Select Committee on Animals in Scientific Procedures, on 23 April 2002. 5 Professor Goldberg raised two matters of concern in relation to transgenic animals, the first being the use of transgenic mice with human genes inserted into them. He then said: "The second thing that is of concern is the fact that transgenic primates will soon come into use on a larger basis. There again, I believe from my perspective, that if we are going to be using those animals, let us try to do it in a way that is the most humane."
I was glad to see that Professor Goldberg had raised these concerns, but also rather disturbed by his apparent acceptance that the use of transgenic primates on a larger scale is inevitable. Given the relative lack of control on laboratory animal use in the USA, he was undoubtedly being realistic.
The scientific justification for using genetically modified primates would be very hard to establish convincingly. Much more relevant information could be obtained by increasing clinical research on patients.
This leads to another matter that disturbs me greatly. Various people have told me that the dog is likely to be used less and less as the second species in toxicity tests on pharmaceuticals, since nonhuman primates are becoming the favoured models.
Furthermore, primates are also being proposed as substitutes for cats in vision research, and even in studies on reproductive toxicity and endocrine disruption, in addition to studies -of questionable value -in rodents.
Thus there are a number of appalling prospects before us, including an increase in the production and use of transgenic primates, and increases in the use of primates in toxicity testing and in basic research.
Some will say that these developments are taking place in the USA and will not occur in the UK, where, as we are so often told, "We have the world's strongest laboratory animal protection law and regulations". This does not convince me, especially as those who conduct laboratory animal-based research appear to have been successful in convincing Government ministers (including even the Prime Minister) and the House of Lords Select Committee 6 that the ways in which the requirements of the Animals (Scientific Procedures) Act 1986 are operated, not least in relation to the production and use of transgenic animals, threaten the freedom and competitiveness of British science and industry.
It is high time that the counter-arguments were repeated and listened to.
The UK does not have a good record on the use of non-human primates, despite the promises of a long series of Government ministers.
Editorial

Animal Experiments: Are There No Limits?
At the 3rd World Congress on Alternatives and Animal Use in the Life Sciences, held in Bologna in 1999, I expressed my concern that 2475 procedures involving Old World monkeys had begun in the UK in 1998, an increase of 31% over the 1997 figure. 7 In 2001, as the Home Office statistics published in July 2002 reveal, 8 the number of procedures involving Old World monkeys was 2597, an increase of 18% over the number in 2000, and even higher than the 1998 number. This puzzles me, not least because most of these animals will have been used in pharmaceutical testing, yet, because of mergers we have a dwindling number of pharmaceutical companies.
There is a constructive and reasonable way out of this. In my Bologna presentation, I proposed an eight-point strategy for achieving the zero option for non-human primate use in Europe, in less than ten years. This proposal appears to have had no impact whatsoever.
Must I plough a lone furrow? Is there nobody out there who will lend me their support?
Michael Balls
